Level Bio AbNGM: LEVBIO

LEVBIO: Q2 sales grew 10% year-over-year, with H2 growth expected from new products

· Issued by Level Bio AB

Q2 2024 saw a 10% sales increase and improved gross margin, but H1 sales fell 17% year-over-year. Liquidity was strengthened post-period via a 1.75 MSEK share issue, and management expects new products to drive growth in H2.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.